Francais (Fr)English (United Kingdom)
Recherche
Actualités

Francis Lévi, Warwick Medical School, University of Warwick, July 21, 2014:

- Circadian control of xenobiotic carcinogenesis and cancer pharmacology

- Toward Systems Cancer Chronotherapeutics and its integration into home care 

La Société Francophone de Chronobiologie (SFC) organise son 44ème congrès qui se déroulera du 29-31 octobre 2014

Séance de la Société de Biologie " La chronobiologie " aura lieu le 15 octobre 2014 de 15h00 à 18h00 Institut Curie-Pavillon Curie Amphithéâtre Marie Curie 11, rue Pierre et Marie Curie – Paris 5ème

La soutenance de thèse de Melle Véronique ROCHE sera présentée le 21 mai 2014

Reportage BBC, 13 mai 2014  Chronotherapy: The science of timing drugs to our Body

Journal "Le monde" le 30 avril 2014, "Quand l'horloge biologique se détraque"

 

Voir la suite

Contact

UMRS 935

Equipe3 : Chronothérapie des cancers

et optimisation de la fonction hépatique

INSERM et Université Paris Sud

Bât A 3ème étage Campus CNRS
7 rue Guy Môquet
94801 Villejuif Cedex (France)
Tel :  +33 (0) 1 49 58 34 83
Fax : +33 (0) 1 49 58 34 59
Email:gladys.germe@inserm.fr

Home Projets et coopérations Projets

Recherche Technologique


 

Capteurs à empreintes moléculaires polymériques de nucléosides modifiés pour un suivi, non-invasif, de thérapies de cancers

The overall objective of this proposal is to develop and to validate a quantitative, noninvasive diagnosis tool to monitor the efficacy of chemotherapy in patients with colorectal cancer and to follow up these patients after surgical eradication of their disease, even at a metastatic stage.

A methodology will be developed making use of a combination of the probably most exciting recent advances in the field of acoustic-biosensor based on molecularly imprinted polymers (MIP). It includes advances which will take the sensitivity down to a low-concentration single-molecule level. Apart from detecting and identifying tumour markers in the urine samples, the effect of circadian chemotherapy on the amount of cancer markers, using the developed tools will be explored.

In fact, the circadian timing system is composed of molecular clocks, which drive 24-h changes in xenobiotic metabolism and detoxification, cell cycle events, DNA repair, apoptosis, and angiogenesis. As a result, circadian timing can modify 2- to 10-fold the tolerability of anticancer medications in experimental models and in cancer patients. This is to date an almost unexploited dimension for diagnosis information.

By combining and supporting these novel optical methods with state-of-the-art affinity molecule MIP technology, tumour biomarkers, acoustic biosensor, will be exploited to extract a maximum amount of information out of very small amounts of sample material. Given the high incidence of colorectal cancer, this project has a very high relevance.

RBC has developped three translational studies, which explore the changes in the urinary excretion of modified nucleosides in patients with colorectal cancer. The studies involve the modifications of these urinary markers according to circadian rhythms, chemotherapy and surgery. These protocols have been activated in september 2012.

In a cooperation with Stanford University (Pr. D. Spiegel team), RBC will evaluate the circadian modifications of these markers in breast metastatic cancer.

Equipes participantes :

Luigi Agrofoglio (coordonnateur), Institut de Chimie Organique & Analytique, Orléans, France

Dominique Rebière, Laboratoire de l'Intégration du Matériau au Système, Bordeaux, France

Christophe Junot and Alain Pruvost, Service de Pharmacologie et d'Immunoanalyse, CEA, Saclay, France

Francis Lévi, RBC, INSERM U776, Villejuif, France

Richard Vidal, Merck Chimie SAS – Estapor, Pithiviers, France

<-retour

 

Mise à jour le : 22/04/2015

Copyright © 2011 ---.
All Rights Reserved